Shenzhen Reetoo Biotechnology Co., Ltd, a Chinese firm at the forefront of integrating artificial intelligence with medical diagnostics, has reportedly secured over RMB 100 million (USD 14 million) in a Series B2 financing round. The round was led by CAS Investment and a prominent Chinese fund, with additional participation from Shenzhen Investment Holdings Capital. The funds raised will be directed towards the manufacturing, commercialization, and R&D of the company’s core assets.
Established in 2017, Reetoo Bio specializes in the deep integration of AI with medical diagnosis, developing a suite of intelligent analysis systems spanning clinical examination, blood, pathology, and reproductive medicine. The company’s product offerings cater to a variety of testing scenarios, including the analysis of blood, body fluids, tissues, sputum, and more.- Flcube.com
